EU IVDR Manufacturer Obligations under Article 10

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

Article 10 is the skeleton of manufacturer obligations and contains 15 paragraphs. Four are central: Article 10(4) requires the technical documentation to be drawn up and kept up to date (in line with Annexes II and III); Article 10(7) requires the technical documentation, the EU declaration of conformity and copies of certificates to be kept for at least 10 years, counted from the date on which the last device covered by the declaration of conformity was placed on the market; Article 10(8) requires a quality management system covering at least thirteen aspects, (a) to (m); and Article 10(9) requires a post-market surveillance system in accordance with Article 78.

The remaining paragraphs allocate the rest of the compliance perimeter: risk management, declaration of conformity and CE marking, UDI and registration, language duties for accompanying information, corrective action and reporting duties, cooperation with authorities, and financial coverage of liability. Because notified body audits walk the Article 10 list clause by clause, an obligation register mapped to its fifteen paragraphs is the fastest way to present a complete picture at assessment.

2. Legal basis

The table below lists the provisions of Article 10 and the annexes it references.

Regulation / documentProvisionDateSource
Regulation (EU) 2017/746 (IVDR)Article 10(4) (technical documentation); Article 10(7) (retention for at least 10 years); Article 10(8) (QMS, items (a) to (m)); Article 10(9) (PMS); Article 10(2) (risk management); Article 10(3) (performance evaluation including PMPF)Adopted 2017-04-05; applies from 2022-05-26EUR-Lex
Same regulationArticle 10(5) (declaration of conformity and CE marking); Article 10(6) (UDI and registration duties under Articles 26 and 28); Article 10(10) (accompanying information and language); Articles 10(11) to 10(13) (corrective actions, notification, cooperation with authorities); Article 10(15) (financial coverage of liability)2017-04-05EUR-Lex
Same regulationAnnex II (technical documentation); Annex III (technical documentation on post-market surveillance)2017-04-05EUR-Lex

Articles 78 and 79 and Annex XIII Part B, which define the PMS system the manufacturer must operate, are covered in the dedicated parts of this series on post-market surveillance; the register should cross-reference them.

3. Expert insights

Insight 1: the technical documentation is a living file, not a one-time deliverable.

Article 10(4) uses the wording draw up and keep up to date. Read together with Article 56(6), under which the performance evaluation and the PER must be updated throughout the life cycle using PMPF data, with at least annual updates for Class C and D devices, and with the change management requirement in Article 10(8)(a), the update frequency and intensity of the technical documentation are driven jointly by the risk class and by the rate of change of the product. A documentation plan without scheduled update triggers will drift, and the drift surfaces as nonconformities at the next audit.

Insight 2: the 10-year retention period starts from the last device placed on the market.

Under Article 10(7), the retention period runs from the date on which the last device covered by the EU declaration of conformity was placed on the market, and lasts at least 10 years. Discontinuation therefore does not start the clock; it freezes the countdown until the final placement. Non-EU manufacturers must additionally ensure, under the third subparagraph of Article 10(7), that the authorised representative has permanent availability of the documentation necessary to carry out the tasks under Article 11(3). Retention policy must therefore be defined at system level, with owners, access paths and the authorised representative arrangement all documented.

Insight 3: three of the thirteen QMS aspects are the most frequently underestimated.

Of the aspects listed in Article 10(8), three stand out as additions or intensifications relative to the IVDD: (a) the regulatory compliance strategy and change management procedures, (f) performance evaluation including PMPF, and (i) the establishment, implementation and maintenance of the post-market surveillance system. Manufacturers who simply carry over existing ISO 13485 procedures usually cannot produce evidence for these three items, because the IVDR-specific content, the compliance strategy document, the PMPF plan and the PMS system file, has no direct counterpart in the inherited procedures.

Insight 4: Article 10(15) ties liability risk to financial arrangements.

Manufacturers must, in proportion to the risk class, the type of device and the size of the enterprise, take measures to provide sufficient financial coverage for their potential liability under Directive 85/374/EEC. This paragraph directly shapes the insurance and guarantee arrangements negotiated between non-EU manufacturers and their authorised representatives, and it connects to the joint-liability discussion elsewhere in this series. Financial coverage should be reviewed whenever the portfolio shifts toward higher classes, since the proportional requirement moves with the class mix.

4. Practical recommendations

  1. Use the fifteen paragraphs of Article 10 as the table of contents for an obligation-to-evidence-to-owner register, and land each paragraph in practice.
  2. Compile the technical documentation as two volumes per Annexes II and III, and define update triggers (changes, PMS data, standard updates).
  3. Define the document retention policy at system level: retention period, responsible person, access path, and availability for the non-EU authorised representative.
  4. Number the QMS procedure files against the thirteen aspects (a) to (m) one by one, so that notified body auditors can locate them directly.
  5. Write the nonconformity handling, notification and cooperation duties of Articles 10(11) to 10(13) as standard operating procedures that have been rehearsed, not merely drafted.

5. Verification checklist

  • □ Technical documentation established under Article 10(4) and Annexes II and III, and kept up to date
  • □ Retention rule defined: at least 10 years from the last device placed on the market (Article 10(7))
  • □ QMS covering the thirteen aspects (a) to (m) of Article 10(8)
  • □ Post-market surveillance system in place under Article 10(9) and Article 78
  • □ Non-EU manufacturer ensured permanent availability of documents to the authorised representative (third subparagraph of Article 10(7))
  • □ Financial coverage of potential liability reviewed (Article 10(15))

Regulatory information verified as of 29 October 2026.

GRZAN builds Article 10 obligation registers, structures IVDR technical documentation to Annexes II and III, and designs QMS procedures that map demonstrably onto the thirteen aspects of Article 10(8) for the EU IVDR market. For tailored compliance support, contact info@grzanglobal.com.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail